Greta Heckmann
Psychiatric/Mental Health · Dalton, GANPI 1427658368
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Teva Pharmaceuticals USA, Inc. accounts for 68.6% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $11,870, 8.3 times the $1,436 reported in 2021. Among psychiatric/mental health clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 462 payments — averaging $61.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$19K
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Johnson & Johnson$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$871
- plus $2K from 14 others
What the payments were for
- Consulting fees$3301%
- Speaking & faculty fees$12,88145%
- Travel & lodging$3,57813%
- Food & beverage$11,44340%
- Education$1651%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 106 | $19,485 |
| AbbVie | 124 | $2,232 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 69 | $1,644 |
| Johnson & Johnson | 23 | $1,270 |
| Otsuka America Pharmaceutical, Inc. | 34 | $1,061 |
| Alkermes, Inc. | 24 | $871 |
| Axsome Therapeutics, Inc. | 16 | $508 |
| Neurocrine Biosciences, Inc. | 22 | $470 |
| Vanda Pharmaceuticals Inc. | 15 | $275 |
| Lundbeck LLC | 9 | $174 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $126 |
| Supernus Pharmaceuticals, Inc. | 5 | $89 |
| Almatica Pharma LLC | 2 | $40 |
| Harmony Biosciences LLC | 1 | $32 |
| Indivior Inc. | 1 | $29 |
| Luye Pharma (USA) Ltd. | 1 | $23 |
| Noven Therapeutics, LLC | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Tris Pharma Inc | 1 | $17 |
| Neos Therapeutics, LP | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$17,361
- LYBALVI$983
- VRAYLAR$946
- INVEGA SUSTENNA$609
- CAPLYTA$582
- ARISTADA$410
- REXULTI$351
- ABILIFY MAINTENA$247
- AUSTEDO$247
- Auvelity$231
- UZEDY$223
- SPRAVATO$217
- ABILIFY ASIMTUFII$122
- ARISTADA INITIO$102
How this compares
$28,398 in reported general payments places this provider in the 95th percentile of 900 psychiatric/mental health providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 53 | $415,734 |
| IngrezzaValbenazine Tosylate | 29 | $246,090 |
| RexultiBrexpiprazole | 41 | $72,372 |
| CaplytaLumateperone Tosylate | 24 | $38,927 |
| TrintellixVortioxetine Hydrobromide | 34 | $19,097 |
| VraylarCariprazine Hcl | 13 | $18,384 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $18,117 |
| Lurasidone Hcl | 27 | $5,778 |
| Aripiprazole | 46 | $4,771 |
| Ramelteon | 33 | $3,073 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 14 | $2,270 |
| Vilazodone Hcl | 12 | $1,941 |
| Quetiapine Fumarate | 103 | $1,893 |
| Ziprasidone Hcl | 32 | $1,449 |
| Duloxetine Hcl | 63 | $1,233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $19,485 | $415,73453 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $470 | $246,09029 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,061 | $72,37241 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,644 | $38,92724 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $126 | $19,09734 claims |
| AbbVieVraylar | $2,232 | $18,38413 claims |
| Alkermes, Inc.Lybalvi | $871 | $18,11711 claims |
| Almatica Pharma LLCSertraline Hcl | $40 | $12245 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatric/mental health providers in Georgia.
Other psychiatric/mental health in Dalton
- Laura PriestDalton$5K
- Phyillis Kennedy-HowellBarney$673K
- Jessica OliverThomasville$233K
- Sherri KrollBrunswick$155K
- Taylor LeblancAlbany$48K
- Matthew DowdyWoodstock$25K
- Natasha GilesLoganville$21K
- Darrick SealeyWarner Robins$17K
- Olufunke AdewunmiSmyrna$13K
- Bradley MosherSuwanee$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.